Last reviewed · How we verify
Arestin
At a glance
| Generic name | Arestin |
|---|---|
| Also known as | Minocycline Hydrochloride |
| Sponsor | University of South Carolina |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Minocycline as Adjunctive Treatment for Treatment Resistant Depression (PHASE3)
- Optimization of Minocycline for Helicobacter Pylori Rescue Treatment (PHASE4)
- Minocycline in Stroke Study at Maimonides (PHASE2, PHASE3)
- Comparing Two Medicines for Healing Jaw Bone Infections After Root Canal Treatment (NA)
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- Topical Minocycline for CARP (EARLY_PHASE1)
- Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke (PHASE2)
- Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arestin CI brief — competitive landscape report
- Arestin updates RSS · CI watch RSS
- University of South Carolina portfolio CI